Chemed Corporation (CHE) – What Are Researchers Thinking About This Stock?

Shares of Chemed Corporation (NYSE:CHE) have been assigned a consensus rating of “Hold” from the seven brokerages that are currently covering the stock, Marketbeat reports. Five analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $554.60.

A number of research firms recently commented on CHE. Wall Street Zen upgraded Chemed from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 10th. Oppenheimer increased their target price on Chemed from $500.00 to $590.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Royal Bank Of Canada increased their target price on Chemed from $436.00 to $548.00 and gave the company a “sector perform” rating in a report on Thursday, July 30th. Bank of America reissued a “neutral” rating on shares of Chemed in a research report on Wednesday, July 29th. Finally, Weiss Ratings upgraded Chemed from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th.

Chemed Trading Down 0.8%

Shares of CHE stock opened at $508.20 on Tuesday. The company has a current ratio of 0.91, a quick ratio of 0.89 and a debt-to-equity ratio of 0.17. Chemed has a 12-month low of $365.20 and a 12-month high of $557.00. The stock has a market capitalization of $6.64 billion, a P/E ratio of 25.52, a P/E/G ratio of 2.06 and a beta of 0.51. The firm’s 50 day moving average is $516.74 and its 200 day moving average is $472.72.

Chemed (NYSE:CHE) last announced its earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share for the quarter, beating analysts’ consensus estimates of $5.60 by $0.46. The business had revenue of $673.25 million during the quarter, compared to analyst estimates of $665.04 million. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same period in the previous year, the business earned $4.27 EPS. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Research analysts expect that Chemed will post 23.55 earnings per share for the current year.

Chemed Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th were paid a $0.70 dividend. This is a boost from Chemed’s previous quarterly dividend of $0.60. The ex-dividend date was Monday, August 17th. This represents a $2.80 annualized dividend and a dividend yield of 0.6%. Chemed’s dividend payout ratio (DPR) is currently 14.06%.

Insider Buying and Selling

In related news, EVP Spencer Lee sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $541.04, for a total value of $541,040.00. Following the transaction, the executive vice president owned 13,912 shares of the company’s stock, valued at approximately $7,526,948.48. This trade represents a 6.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Patrick Grace sold 190 shares of the business’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $532.00, for a total transaction of $101,080.00. Following the sale, the director owned 3,533 shares of the company’s stock, valued at $1,879,556. This trade represents a 5.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 9,190 shares of company stock valued at $4,833,160. 3.33% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP purchased a new stake in shares of Chemed in the second quarter valued at $1,726,000. The Manufacturers Life Insurance Company bought a new stake in shares of Chemed in the 2nd quarter worth about $4,413,000. Lone Peak Global Investors LLC lifted its holdings in shares of Chemed by 38.1% in the 2nd quarter. Lone Peak Global Investors LLC now owns 37,099 shares of the company’s stock worth $17,279,000 after acquiring an additional 10,226 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in shares of Chemed by 41.7% in the 2nd quarter. Hsbc Holdings PLC now owns 12,346 shares of the company’s stock worth $5,729,000 after acquiring an additional 3,632 shares during the last quarter. Finally, Amundi boosted its stake in shares of Chemed by 51.5% during the 2nd quarter. Amundi now owns 53,856 shares of the company’s stock worth $25,083,000 after purchasing an additional 18,301 shares during the period. 95.85% of the stock is currently owned by institutional investors.

Chemed Company Profile

Chemed Corporation (NYSE:CHE) is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.

VITAS Healthcare is a provider of hospice and palliative care for individuals with advanced illnesses. The business delivers care in patients’ homes, hospice inpatient units, hospitals, nursing facilities and other care settings.